Story perspectives

RYZ101 Phase 3 ACTION-1 Trial Shows Significant PFS Benefit

By Drooid · Oct 13, 2026, 2:35 AM UTC · How we work

Summary

BMS Announces PFS

Bristol Myers Squibb reported that RYZ101 improved progression-free survival in the Phase 3 ACTION-1 trial.
The trial met its primary endpoint with a statistically significant progression-free survival benefit.
RYZ101 was compared with investigator-selected standards such as high-dose somatostatin analogues, everolimus or sunitinib.
Safety findings in the trial aligned with RYZ101’s known safety profile.
The FDA granted RYZ101 orphan-drug designation for GEP-NETs in August 2026.

Summary

BMS Shares Surge

Bristol Myers Squibb shares rose about 6% in pre-market trading, reaching $62.50 after dual Phase 3 announcements.
The S&P 500 stayed flat, showing the rally was company-specific.
J.P. Morgan maintained a Buy rating and analysts raised price targets ahead of the October 29 earnings release.
Analysts project the 60 mg admilparant dose could generate roughly $1.3 billion in sales by 2032.
A positive safety profile allayed investor concerns after a prior liver-safety signal.

1 of 2

BMS Announces PFS

Bristol Myers Squibb reported that RYZ101 improved progression-free survival in the Phase 3 ACTION-1 trial.
The trial met its primary endpoint with a statistically significant progression-free survival benefit.
RYZ101 was compared with investigator-selected standards such as high-dose somatostatin analogues, everolimus or sunitinib.
Safety findings in the trial aligned with RYZ101’s known safety profile.
The FDA granted RYZ101 orphan-drug designation for GEP-NETs in August 2026.

1 / 2